084 - Navigating the Neurodegenerative Disease Subsector | $CRTX $AVXL $ALEC $CYCN $SAVA

[@krishnach1333]

Thanks for such a in-depth analysis. I bought few AVXL. Bought SAVA at 47 and sold around 67. I sold bluebird bio, bought more Intellia and Beam ..

[@cloudbuster77]

AVXL has biggest potential of those companies. He just scratched the surface of what its been up to

[@ciresica86]

Thanks Matt! This is a great video.

[@breakingbiotech]

Thank you!

[@anonymous62810]

Great video! I'm still going through your video but noticed you don't make mention of $ATHA - it's HGF/MET small molecule company with 2 ongoing phase 2 trials and had good safety data on phase 1 with positive signal regarding cognitive biomarkers including P300 and gamma EEG. Perceptive is a big investor with Eddleman sitting on the board. I realize there are too many to cover but wanted to get your take? Thanks for all you do!

[@breakingbiotech]

I will touch on them in a follow up episode

[@tallseahorses]

thank you for your videos. they are very helpful. Does $ANVS also interest you as well?

[@breakingbiotech]

I will touch on them in an upcoming episode. Thanks

[@tallseahorses]

@@breakingbiotech Another fascinating company/drug - $FREQ they are curing hearing loss. in the middle of phase 2.

[@julioduarte6973]

And CYTH?

[@rafaqabran8354]

I'm shorting Cortexyme if they end up following through with their COR388

[@kbram7363]

Dude we need an update video on Anavex

[@smaktat]

Have you talked about Covaxin in any of your videos?

[@breakingbiotech]

I have not

[@prosperousguy]

Excellent Matt, glad I stumbled onto you. I'm a 40 year trader of various Pharma/Biotech stocks. I focus on the technical patterns and gather my fundamental research from Pros like you. Thx and if you ever want charts done on a few like $AUPH that you just added to your position, feel free to ask

[@breakingbiotech]

Thank you for the offer, I will keep you in mind.

[@matthewbehnke848]

Thanks matt!

[@stargazer2455]

Where’s Athira?? Edelman has a huge stake here.. Their approach is worthy of a mention

[@breakingbiotech]

Too many companies to cover but I will touch on them in an upcoming episode.

[@julioduarte6973]

And $CYTH?